Additionally, when we use a GPCR142 antibody to block the binding of INSL5 and GPCR142, it also diminished INSL5 oncogenic function (Fig EV5B), which indicated that GPCR142 antibody can be potential therapeutic strategy for NPC. The gene discussed is INSL5; the disease is nasopharyngeal carcinoma.